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MaOBJECTIVES The aim of this meta-analysis was to evaluate and compare the efﬁcacy of the 2 different neuroprotection
systems in preventing embolization during carotid artery stenting (CAS), as detected by diffusion-weighted magnetic
resonance imaging (DW-MRI).
BACKGROUND Data from randomized and nonrandomized studies comparing both types of embolic protection devices
revealed contrasting evidence about their efﬁcacy in neuroprotection, as assessed by the incidence of new ischemic
lesions detected by DW-MRI.
METHODS Eight studies, enrolling 357 patients, were included in the meta-analysis. Our study analyzed the incidence of
new ischemic lesions/patient, comparing ﬁlter cerebral protection and proximal balloon occlusion.
RESULTS Following CAS, the incidence of new ischemic lesions/patient detected by DW-MRI was signiﬁcantly lower in
the proximal balloon occlusion group (effect size [ES]: 0.43; 95% conﬁdence interval [CI]: 0.84 to 0.02, I2 ¼ 70.08,
Q ¼ 23.40). Furthermore, following CAS, the incidence of lesions at the contralateral site was signiﬁcantly lower in the
proximal protection group (ES: 0.50; 95% CI: 0.72 to 0.27, I2 ¼ 0.00, Q ¼ 3.80).
CONCLUSIONS Our meta-analysis supports the concept that the use of proximal balloon occlusion compared with
ﬁlter cerebral protection is associated with a reduction of the amount of CAS-related brain embolization. The data should
be conﬁrmed by a randomized clinical trial. (J Am Coll Cardiol Intv 2014;7:1177–83) © 2014 by the American College of
Cardiology Foundation.C arotid artery stenting (CAS) is a validatedtreatment to reduce the incidence of strokeamong patients with moderate-to-severe
symptomatic carotid stenosis (1,2), as well as among
those with severe asymptomatic carotid stenosis
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CI = conﬁdence interval
DW-MRI = diffusion-weighted
magnetic resonance imaging
EPD = embolic protection
device
ES = effect size
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1178Among the EPDs that are in clinical use,
proximal EPDs have the advantage of
providing cerebral embolic protection during
all phases of the endovascular intervention
(6). The use of endovascular clamping, a
proximal EPD, during CAS has been demon-
strated to be particularly safe and efﬁcient in
large registries and clinical trials (7,8). More-
over, the use of proximal EPDs has been
associated with a reduced amount of cere-bral embolic signals when compared with distal
protection devices (6).
Diffusion-weighted magnetic resonance imaging
(DW-MRI) has been shown to be a sensitive tool in
identifying new ischemic cerebral lesions caused by
emboli during CAS. Data from randomized and non-
randomized studies comparing both types of EPDs
revealed contrasting evidence about their efﬁcacy in
neuroprotection, as assessed by the incidence of new
ischemic lesions detected by DW-MRI (9–16).
Therefore, the aim of this meta-analysis was to
evaluate and compare the efﬁcacy of the 2 different
neuroprotection systems in preventing embolization
during CAS, as detected by DW-MRI.
METHODS
STUDY SELECTION. The study was designed accord-
ing to PRISMA (Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses) requirements
(17). MEDLINE, Cochrane (Cochrane Database of Sys-
tematic Reviews), Web of Science, and SCOPUS data-
base were searched for studies published until
December 2013. Studies were identiﬁed using the
major medical subject heading “carotid artery stent-
ing or CAS” AND “DW-MRI or magnetic resonance
imaging” AND “distal embolic protection device or
ﬁlter or distal cerebral protection” AND “proximal
embolic protection device or ﬂow reversal or proximal
cerebral protection.” Citations were screened at the
title and abstract level, and retrieved as a full report
if they reported data on the comparison of
CAS outcomes, deﬁned as new ischemic lesions
detected at DW-MRI, between a ﬁlter cerebral pro-
tection group and a proximal balloon occlusion group.
No language limitations were applied. The full texts
and bibliography of all potential studies also were
retrieved in detail to seek additional relevant studies.
INCLUSION CRITERIA. Studies were included if they:
1. Reported data on comparison of CAS out-
comes, deﬁned as the incidence of new ischemic
lesions and number of new ischemic lesions per
patient (lesions/patient), between a ﬁlter cerebralprotection group and a proximal balloon occlusion
group; and
2. New ischemic lesions were detected by DW-MRI.
EXCLUSION CRITERIA. Studies were excluded if any of
the following criteria applied:
1. Duplicate publication, subgroup studies of a main
study;
2. The outcome of interest was not clearly reported or
was impossible to extract or calculate from the
published results.
DATA EXTRACTION. Two reviewers independently
screened studies for fulﬁlment of inclusion criteria.
Reviewers compared selected trials, and discrep-
ancies were resolved by consensus. The quality of the
trials was not evaluated because this practice has
been previously discouraged (18).
STUDY ENDPOINTS. The primary endpoint evaluated
was the incidence of new ischemic lesions/patient
during a CAS procedure with ﬁlter cerebral protection
or proximal balloon occlusion. Publication bias was
assessed by plotting the study results against the
precision of the study (funnel plots) for each
outcome. Symmetry of the funnel plots was tested
using the trim and ﬁll method. Of the 193 studies
identiﬁed by the initial search, 12 were retrieved for
more detailed evaluation, and 8 studies were
included in the study (Figure 1).
STATISTICAL ANALYSIS. Mean, SD, and p values
were used. Overall estimates of effect (effect size
[ES]) were calculated with a random effects model
(19). Statistical signiﬁcance was set at p < 0.05
(2-tailed). Heterogeneity was assessed by a Q statistic
and I2 test. Signiﬁcant heterogeneity was considered
present for p values <0.10 or an I2 >50%. Data anal-
ysis was performed using ProMeta 2.0 (Internovi,
Cesena, Italy). For veriﬁcation of the robustness of
the results, sensitivity analyses were performed to
test the inﬂuence of potential effect modiﬁers,
including mean age, age >80 years, male sex, symp-
tomatic carotid artery disease, smoking status, dia-
betes, coronary artery disease, chronic obstructive
pulmonary disease, peripheral artery disease, hyper-
tension, dyslipidemias, prior myocardial infarction,
prior stroke, prior transient ischemic attack, and
study publication year.RESULTS
CHARACTERISTICS OF INCLUDED CLINICAL TRIALS.
Of the 193 studies identiﬁed by the initial search, 12
FIGURE 1 Meta-Analysis Flow Chart
Flow diagram demonstrating study selection for meta-analysis (PRISMA [Preferred Reporting Items for Systematic Reviews and
Meta-Analyses] diagram).
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 7 , N O . 1 0 , 2 0 1 4 Stabile et al.
O C T O B E R 2 0 1 4 : 1 1 7 7 – 8 3 Embolic Protection During Carotid Artery Stenting
1179were retrieved for more detailed evaluation. Four
studies were subsequently excluded, and therefore, 8
studies were ﬁnally included in the analyses,
enrolling 357 patients (Figure 1). No signiﬁcant limi-
tations were identiﬁed for 8 studies, 5 of which were
randomized trials (9,11,12,14,15), whereas 3 were
nonrandomized comparisons (13,16,20) (Table 1).
INCIDENCE OF NEW ISCHEMIC LESIONS/PATIENT
AT DW-MRI. The number of new ischemic lesions/
patient detected by DW-MRI was signiﬁcantly lower
in the proximal balloon occlusion group (ES: 0.43;
95% conﬁdence interval [CI]: 0.84 to 0.02,
I2 ¼ 70.08, Q ¼ 23.40) (Figure 2).
INCIDENCE OF NEW ISCHEMIC LESIONS AT THE
CONTRALATERAL SITE AT DW-MRI. Following CAS,
the incidence of new ischemic lesions detected at thecontralateral site by DW-MRI was signiﬁcantly lower
in the proximal protection group (ES: 0.50; 95%
CI: 0.72 to 0.27, I2 ¼ 0.00, Q ¼ 3.80) (Figure 3).
META-REGRESSION ANALYSIS. Meta-regression anal-
ysis showed no relationship between all the analyzed
modiﬁers and both the incidence of new ischemic
lesions and the number new ischemic lesions/patient.
These results should be considered with caution,
given the limited number of reports, which weakens
the meta-regression analysis itself.
SENSITIVITY ANALYSIS. Results were conﬁrmed when
meta-analyses were repeated, removing 1 study at
a time.
PUBLICATION BIAS. The trim and ﬁll method did not
show any publication bias in any of the analyses
performed.
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1180DISCUSSION
This meta-analysis suggests that the use of proximal
balloon occlusion during CAS is associated with a
signiﬁcant reduction of the number of distal emboli-
zations, when compared with the use of distal EPDs.
A signiﬁcant reduction in the number of distal em-
bolizations is also evident at the site contralateral to
the target vessel.
It is accepted that EPDs lower the risk of stroke
with CAS. In theory, proximal EPDs may provide
better neuroprotection for 2 important reasons (6):
1. A proximal EPD affords neuroprotection through-
out all phases of the procedure, including initial
lesion crossing, whereas distal EPDs must cross
the lesion before neuroprotection can be affor-
ded; and
2. A proximal EPD is able to capture particulate debris
with higher efﬁciency.
DW-MRI is a valuable tool for the detection of focal
brain ischemia in the acute stage. It has been used for
the detection of cerebral embolism after acute
ischemic neurological events and for the detection of
silent ischemic brain lesions after carotid endarter-
ectomy, stenting, and diagnostic cerebral angiog-
raphy (21). Importantly, the occurrence of new
cerebral lesions using DW-MRI should be considered
a surrogate marker of embolization because the
greater part of these lesions remained asymptomatic
and did not have a prognostic impact at 30 days of
follow-up (22). However, it should be considered that
currently, because of the small incidence of CAS-
related symptomatic lesions, it is difﬁcult to estab-
lish the superiority of one EPD compared with
another on the basis of the ability to reduce clinically
relevant neurological events.
The use of proximal protection has been incon-
sistently reported to be a valid tool to reduce the
occurrence of post-CAS new lesions. Subcohort
analysis from a 53-patient randomized trial, com-
paring Mo.Ma (Invatec, Roncadelle, Italy) versus
FilterWire (Boston Scientiﬁc, Natick, Massachusetts)
protection for the treatment of extracranial carotid
atherosclerosis, showed robust reduction in the
occurrence of new ischemic lesions when proximal
protection was used, with a 42.8% (9 of 21) rate in the
ﬁlter group and 14.3% (2 of 14) in the Mo.Ma group
(11). Similarly, another 62-patient randomized trial
comparing the use of proximal versus distal protec-
tion for CAS reported a dramatic difference between
proximal and distal protection in the proportion of
patients with new ischemic lesions (45.2% vs. 87.1%,
p < 0.001) (5).
FIGURE 2 Incidence of New Ischemic Lesions/Patient at DW-MRI
Forrest plot representing the pooled estimate analysis for overall incidence of new ischemic lesions/patient detected at diffusion-weighted
magnetic resonance imaging (DW-MRI). CI ¼ conﬁdence interval; ES ¼ effect size.
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1181A recent comparative trial between a ﬁlter device
(Angioguard, Cordis, East Bridgewater, New Jersey)
and the Mo.Ma system showed a lack of a signiﬁcant
difference in the proportion of patients with new
ischemic lesions (63.3% vs. 66.7%; p ¼ NS). Despite
this, the number of ischemic cerebral lesions per pa-
tient was signiﬁcantly lower in the Mo.Ma group
(a median of 6 lesions per patient vs. a median of 10
in the Angioguard group, p < 0.001). One patient had
a minor stroke during CAS (1.66%) in the Angioguard
group (14).
Opposite results were recently observed in a
similar single-center trial comparing ﬂow-reversal
EPD (n ¼ 21) to ﬁlter EPD (n ¼ 19); a signiﬁcant
reduction in the incidence (15.8% vs. 47.6%,
p ¼ 0.03), number (0.73 vs. 2.6, p ¼ 0.05), and size
(0.81 vs. 2.23 mm, p ¼ 0.05) of new ischemic lesions
were observed when ﬁlter EPDs were used (15).FIGURE 3 Incidence of New Ischemic Lesions at the Contralateral Si
Forrest plot representing the pooled estimate analysis for overall incide
Abbreviations as in Figure 2.This meta-analysis pooled all the available data
and analyzed the incidence of new ischemic lesions
detected at DW-MRI following CAS. We found that the
number of lesions per patient who underwent
proximal-protected CAS is lower when compared with
distal-protected CAS. The association of proximal
protection with a reduced distal embolization is
consistent at the contralateral site.
STUDY LIMITATIONS. One of the most impor-
tant pitfalls of the primary studies included in this
meta-analysis is represented by the lack of informa-
tion about the experience of physicians performing
CAS procedures. It has now been clearly demon-
strated that the number of procedures performed in
catheterization laboratories inﬂuences the outcome
of CAS procedures (23,24). A different level of expe-
rience on the use of speciﬁc EPDs might contribute tote at DW-MRI
nce of new ischemic lesions at the contralateral site at DW-MRI.
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1182justify, at least in part, the discrepancy between the
studies.
It could be speculated that the differences in post-
CAS distal embolization, highlighted by the analyzed
studies, might be related to plaque echogenicity,
stent design (25,26), and patient responsiveness to
drug therapy (27). Unfortunately, these details have
not been described in all the studies considered,
precluding the possibility of evaluating the effect of
these variables.
Furthermore, concerning the speciﬁc EPDs, despite
all the studies comparing distal with proximal EPDs,
there are some differences among the speciﬁc EPDs
used. Regarding proximal EPDs, most of the studies
included in the meta-analysis adopted the endovas-
cular clamping system, whereas the use of the ﬂow-
reversal system was less common. However, even
if it is not possible to demonstrate that these proce-
dural differences justify the different outcomes, this
hypothesis cannot be excluded.
CONCLUSIONS
Although our meta-analysis suggests a potential
beneﬁt by using proximal balloon occlusioncompared with ﬁlter cerebral protection, it still re-
mains unclear whether or not proximal balloon oc-
clusion is superior to ﬁlter cerebral protection.
However, although a large and well-designed ran-
domized clinical trial is warranted to provide a
deﬁnitive answer, the use of data from registries
represents a valid alternative to draw provisional
conclusions from data analysis. In this regard, it is
important to acknowledge that registries provide a
unique opportunity to generate hypotheses on
contemporary disease evolution and treatment. The
use of a registry is a tool able to advance science by
spotlighting what really happens in actual medical
practice, in contrast to the artiﬁcial environment of a
controlled clinical trial. Finally, although random-
ized clinical trials often provide information on
already established therapies, registries provide a
picture of more modern therapy and help the evo-
lution of them.
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